Mackenzie Financial Corp Akebia Therapeutics, Inc. Transaction History

Mackenzie Financial Corp

$71.6 Billion
Q2 2025

A detailed history of Mackenzie Financial Corp transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 248,602 shares of AKBA stock, worth $549,410. This represents 0.0% of its overall portfolio holdings.

Number of Shares

248,602

Previous 237,558 4.65%

Holding current value

$549,410

Previous $456,000 98.25%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$1.55 - $3.97 $17,118 - $43,844	11,044 Added 4.65%	248,602 $904,000
Q1 2025 May 07, 2025	BUY	$1.69 - $2.84 $172,660 - $290,151	102,166 Added 75.46%	237,558 $456,000
Q4 2024 Feb 14, 2025	BUY	$1.26 - $2.13 $154,037 - $260,396	122,252 Added 930.38%	135,392 $251,000
Q3 2024 Nov 13, 2024	SELL	$0.94 - $1.55 $15,526 - $25,602	-16,518 Reduced 55.69%	13,140 $17,000
Q2 2024 Aug 14, 2024	BUY	$0.86 - $1.63 $4,230 - $8,017	4,919 Added 19.88%	29,658 $30,000
Q1 2024 May 10, 2024	BUY	$1.27 - $2.24 $2,006 - $3,539	1,580 Added 6.82%	24,739 $45,000
Q4 2023 Jan 30, 2024	BUY	$0.8 - $1.28 $5,064 - $8,102	6,330 Added 37.61%	23,159 $28,000
Q3 2023 Oct 25, 2023	SELL	$0.87 - $1.84 $9,021 - $19,080	-10,370 Reduced 38.13%	16,829 $19,000
Q2 2023 Aug 03, 2023	SELL	$0.51 - $1.43 $7,250 - $20,328	-14,216 Reduced 34.33%	27,199 $25,000
Q1 2023 Apr 24, 2023	SELL	$0.56 - $1.15 $14,962 - $30,725	-26,718 Reduced 39.21%	41,415 $23,000
Q3 2022 Oct 07, 2022	BUY	$0.3 - $0.46 $7,602 - $11,656	25,341 Added 59.22%	68,133 $22,000
Q2 2022 Aug 10, 2022	BUY	$0.32 - $0.67 $6,697 - $14,022	20,929 Added 95.73%	42,792 $15,000
Q1 2022 May 13, 2022	BUY	$0.72 - $2.93 $419 - $1,708	583 Added 2.74%	21,863 $16,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $48,092 - $71,075	21,280 New	21,280 $48,000
Q4 2020 Feb 10, 2021	SELL	$2.22 - $3.78 $46,176 - $78,624	-20,800 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $80,146 - $438,624	-33,534 Reduced 61.72%	20,800 $52,000
Q2 2020 Aug 13, 2020	SELL	$6.67 - $13.58 $315,410 - $642,171	-47,288 Reduced 46.53%	54,334 $737,000
Q1 2020 May 14, 2020	BUY	$4.1 - $10.24 $267,328 - $667,668	65,202 Added 179.03%	101,622 $770,000
Q4 2019 Feb 13, 2020	BUY	$3.16 - $6.73 $115,087 - $245,106	36,420 New	36,420 $230,000

Others Institutions Holding AKBA

# of Institutions

174

Shares Held

106M

Call Options Held

134K

Put Options Held

262K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $406M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.

Account

Mackenzie Financial Corp Akebia Therapeutics, Inc. Transaction History